司美格鲁肽7.2mg制剂亮相！平均减重18.7%，最新临床研究结果公布

Core Viewpoint - The STEP UP study demonstrates that the 7.2mg dose of semaglutide significantly improves weight loss and metabolic health in obese patients compared to lower doses and placebo, providing a new treatment option for those who did not achieve desired results with lower doses [5][12]. STEP UP Study Overview - The STEP UP study is a phase 3b, randomized, double-blind, placebo-controlled clinical trial involving 1,407 obese adults (BMI ≥ 30 kg/m²) without diabetes, assessing the efficacy and safety of different doses of semaglutide [6]. - Participants were randomly assigned to three groups: 7.2mg semaglutide (1,005 participants), 2.4mg semaglutide (201 participants), and placebo (201 participants), with a treatment duration of 72 weeks followed by a 9-week follow-up [6]. Primary and Secondary Endpoints - The primary endpoint was the percentage change in body weight from baseline to week 72 comparing 7.2mg semaglutide to placebo, along with the proportion of participants achieving a weight loss of ≥5% [7]. - Secondary endpoints included comparisons of weight percentage changes, waist circumference changes, and proportions of participants achieving weight loss of ≥10%, 15%, 20%, and 25% between the 7.2mg and 2.4mg groups [7]. Results: Significant Weight Loss and Waist Circumference Reduction - The 7.2mg semaglutide group achieved an average weight loss of 18.7%, compared to 3.9% in the placebo group, with an estimated treatment difference (ETD) of -14.8% (p<0.0001) [8]. - Compared to the 2.4mg group, the 7.2mg group also showed greater weight loss (18.7% vs. 15.6%, ETD -3.1%, p<0.0001) [8]. - The proportion of participants losing ≥5% of body weight was significantly higher in the 7.2mg group (90.7%) compared to the placebo group (36.8%) [10]. Weight Loss Proportions - Weight loss ≥10%: 7.2mg group 82.4%, 2.4mg group 75.1%, placebo group 20.5% [10] - Weight loss ≥15%: 7.2mg group 66.5%, 2.4mg group 54.5%, placebo group 7.6% [10] - Weight loss ≥20%: 7.2mg group 47.7%, 2.4mg group 33.3%, placebo group 2.9% [10] - Weight loss ≥25%: 7.2mg group 31.2%, 2.4mg group 15.3%, placebo group 0% [10] Significant Improvement in Metabolic Indicators - The 7.2mg group showed significant improvements in waist circumference, blood pressure, blood lipids, HbA1c, and fasting blood glucose [11]. - Average waist circumference reduction was 17.5cm in the 7.2mg group compared to 5.9cm in the placebo group (ETD -11.7cm, p<0.0001) [11]. - HbA1c decreased by 0.32 percentage points in the 7.2mg group versus 0.02 in the placebo group, and fasting blood glucose decreased by 0.63mmol/L compared to 0.12mmol/L in the placebo group [11]. Conclusion - The STEP UP study results indicate that the 7.2mg semaglutide formulation shows significantly better efficacy and good safety in obesity treatment, offering new options for patients who did not meet treatment goals with lower doses [12].